FRIDAY TOUR 3

DIABETES/PREDIABETES
Poster Number Author Name Title
267 Michael Davies INCIDENCE OF GENITAL MYCOTIC INFECTIONS DECLINES OVER TIME IN PATIENTS WITH TYPE 2 DIABETES MELLITUS TREATED WITH CANAGLIFLOZIN OVER 2 YEARS
268 Deep Dutta INCREASED SERUM FETUIN-A IS AN IMPORTANT ADVERSE PREDICTOR OF GLYCEMIC OUTCOMES IN PREDIABETES: A 4 YEAR PROSPECTIVE STUDY FROM INDIA
269 Sheila Corrigan PHARMACOKINETIC BIOEQUIVALENT AND NON-BIOEQUIVALENT CONCENTRATED INSULIN FORMULATIONS: IMPLICATIONS FOR CLINICAL USE AND DOSING
270 Sheela Metgud OUTCOMES OF A STANDARDIZED PROTOCOL FOR DIABETES MANAGEMENT IN SURGICAL INPATIENTS
271 Luigi Meneghini IMPACT OF PREGABALIN ON SIGNS AND SYMPTOMS OF GASTROPARESIS
272 Rosemarie Lajara EXPERIENCE USING V-GO® IN PATIENTS WITH LATENT AUTOIMMUNE DIABETES OF THE ADULT (LADA) AND TYPE 1 DIABETES
273 Rosemarie Lajara EVALUATING THE EFFECT OF V-GO® THERAPY IN SUB-OPTIMALLY CONTROLLED PATIENTS WITH DIABETES – A RETROSPECTIVE COHORT ANALYSIS IN A LARGE SPECIALIZED DIABETES SYSTEM
274 Carol Smyth ELEVATED AST AND ALT RESULTS AND AN AST/ALT RATIO BETWEEN 0.7 AND 1.0 LINKED TO AN INCREASED RISK OF NASH IN PATIENTS WITH DIABETES